# Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation

> **NCT00396383** · PHASE2 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 9 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** plerixafor

## Key facts

- **NCT ID:** NCT00396383
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-11
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Insufficient cell mobilization for tandem transplants
- **Last updated:** 2014-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00396383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00396383, "Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00396383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*